Stockscreener 앱 받기
1.735
3.40%
-0.045
전일 마감가:
$1.78
열려 있는:
$1.8
하루 거래량:
449.02K
Relative Volume:
0.23
시가총액:
$519.84M
수익:
$6.23M
순이익/손실:
$-95.90M
주가수익비율:
-4.4487
EPS:
-0.39
순현금흐름:
$-68.47M
1주 성능:
-8.05%
1개월 성능:
-13.16%
6개월 성능:
+63.76%
1년 성능:
+13.12%
1일 변동 폭
$1.70
$1.8334
1주일 범위
$1.655
$1.89
52주 변동 폭
$0.6513
$2.17
Precigen Inc Stock (PGEN) Company Profile
명칭
Precigen Inc
전화
301-556-9900
주소
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
PGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.73 | 519.84M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.72 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.23 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.89 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
239.75 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.82 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 개시 | JP Morgan | Neutral |
| 2022-11-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 개시 | Stifel | Buy |
| 2021-02-22 | 개시 | Wells Fargo | Overweight |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-05-08 | 개시 | H.C. Wainwright | Buy |
모두보기
Precigen Inc 주식(PGEN)의 최신 뉴스
Precigen Gene Therapy Pioneer Reveals 2024 Performance: Key Financial Results Coming March 19 - StockTitan
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - Longview News-Journal
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Stock Holdings Increased by Rhumbline Advisers - Defense World
Precigen (PGEN) Projected to Post Earnings on Tuesday - Defense World
Is Precigen Inc’s (NASDAQ:PGEN) Stock On The Decline? - Stocks Register
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Insider Monkey
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Shares Up 7.7%Time to Buy? - MarketBeat
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha
FDA advances Precigen’s gene therapy for respiratory disease By Investing.com - Investing.com Australia
FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering & Biotechnology News
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com Australia
FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive™
Decades in, this Germantown biopharma is on the cusp of bringing its first product to market - The Business Journals
Precigen gets FDA Priority Review for its respiratory tract tumor treatment - MSN
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update By Investing.com - Investing.com South Africa
Precigen Says FDA Accepts for Priority Review Application for Recurrent Respiratory Papillomatosis Treatment - Marketscreener.com
Precigen shares surge on FDA priority review for PRGN-2012 By Investing.com - Investing.com Australia
FDA advances Precigen's gene therapy for respiratory disease By Investing.com - Investing.com Canada
Precigen shares surge on FDA priority review for PRGN-2012 - Investing.com India
FDA advances Precigen's gene therapy for respiratory disease - Investing.com India
FDA advances Precigen’s gene therapy for respiratory disease - Investing.com
Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment - MarketWatch
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire
Should You Invest in Precigen (PGEN)? - MSN
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy? - Nasdaq
Precigen (NASDAQ:PGEN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Precigen (NASDAQ:PGEN) Stock Price Up 8.4%What's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Set Precigen, Inc. (NASDAQ:PGEN) PT at $7.00 - Armenian Reporter
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Precigen (NASDAQ:PGEN) Hits New 52-Week HighHere's What Happened - MarketBeat
Will Precigen's Treatment For Recurrent Respiratory Papillomatosis Cross The FDA Finish Line? - RTTNews
SG Americas Securities LLC Acquires 12,578 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World
PGEN Stock Soars to 52-Week High, Reaching $1.93 Amid Growth - MSN
Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Iridian Asset Management LLC CT - MarketBeat
These Numbers Prove Just How Vibrant The Precigen Inc (NASDAQ: PGEN) Stock Has Been - Stocks Register
Precigen (NASDAQ:PGEN) Shares Up 7.8%Here's Why - MarketBeat
Precigen stock slides after pricing stock offering to raise $30 million - MSN
Exploring 3 High Growth Tech Stocks in the United States - Simply Wall St
Precigen Inc (NASDAQ: PGEN): Performance Review And Forecast - Marketing Sentinel
Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha
Precigen Inc (PGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Precigen Inc 주식 (PGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | Director |
Aug 09 '24 |
Buy |
0.85 |
23,529,411 |
19,999,999 |
64,547,214 |
5.68%
0.28%
자본화:
|
볼륨(24시간):